| 85.63 Delayed Data As of Jun 26 |  -1.98 / -2.26%Today’s Change | 57.00 Today|||52-Week Range 89.30 | +34.66% Year-to-Date |
| Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Jun 19 / Zacks.comZAK - Paid Partner Content | Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock Jun 13 / Zacks.comZAK - Paid Partner Content |
| Merck's Keytruda Gets 2nd Label Expansion Approval in June Jun 19 / Zacks.comZAK - Paid Partner Content | Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study Jun 13 / Zacks.comZAK - Paid Partner Content |
| Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I Jun 13 / Zacks.comZAK - Paid Partner Content | BriaCell???s Novel Technology and Clinical Data Published at the 2019 American Society ... May 28 / GlobeNewswirePNW - Paid Partner Content |
| Previous close | 87.61 |
| Today’s open | 87.54 |
| Day’s range | 85.22 - 88.28 |
| Volume | 1,226,218 |
| Average volume (3 months) | 1,291,333 |
| Market cap | $19.0B |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +180.44% |
| Earnings growth (next 5 years) | +35.60% |
| Revenue growth (last year) | +22.50% |
| P/E ratio | 73.2 |
| Price/Sales | 7.29 |
| Price/Book | 9.82 |
| Today’s change | Today’s % change | |
|---|---|---|
| BMRNBiomarin Pharmaceuti... | -0.87 | -1.04% |
| SGENSeattle Genetics Inc | -1.42 | -2.06% |
| ARRYArray Biopharma Inc | -0.09 | -0.19% |
| MYLMylan NV | +0.01 | +0.05% |
| Next reporting date | July 31, 2019 |
| EPS forecast (this quarter) | $0.28 |
| Annual revenue (last year) | $1.9B |
| Annual profit (last year) | $109.5M |
| Net profit margin | 5.82% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Hervé Hoppenot |
Chief Financial Officer & Executive Vice President Christiana Stamoulis |
Corporate headquarters Wilmington, Delaware |
